Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
Updated results to be presented at ASCO GU 2022 showed sustained efficacy and tumor shrinkage benefits with Cabometyx (cabozantinib) in combination with Opdivo (nivolumab) compared to sunitinib 1 People living with advanced renal cell carcinoma treated with the combination con...
The following slide deck was published by Ipsen S.A. in conjunction with their 2021 Q4 earnings call. For further details see: Ipsen S.A. 2021 Q4 - Results - Earnings Call Presentation
Ipsen S.A. (IPSEY) Q4 2021 Earnings Conference Call February 11, 2022, 8:00 AM ET Company Participants David Loew – Chief Executive Officer Aymeric Le Chatelier – Group Chief Financial Officer Howard Mayer – Head of Research and Development Conference Call Participants Je...
Ipsen S.A. press release (OTCPK:IPSEY): FY GAAP EPS of €7.76. Revenue of €3B (+11.5% Y/Y). Full-year 2022 guidance: Total-sales growth greater than 2.0%, at constant currency vs. estimated growth of 1.48% Y/Y. Core operating margin greater than 35.0% of ...
Strong 2021 financial performance with total-sales growth of 12.3% at CER 1 (growth of 10.7% as reported) and a core operating margin of 35.2% (IFRS operating margin of 29.6%) Exclusive negotiations with Mayoly Spindler to divest Ipsen’s Consumer Healthcare (CHC) busine...
Despite supply chain disruptions and labor shortages, the pharma industry is well-positioned to continue growing due to the increasing medical needs of an aging population and advancements in treating chronic diseases. Therefore, amid current market volatility, we believe it could be wise to ...
The global launch of Bylvay was more successful than expected and Albireo doubled its net sales guidance for 2021. Beyond Odevixibat, Albireo was able to discover new drugs with blockbuster. Both early clinical assets address a market with a high medical need and have blockbuster ...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the Health Canada approval of Sohonos (palovarotene capsules), an oral selective retinoic-acid receptor gamma (RARγ) agonist indicated to reduce the formation of heterotopic ossification (HO; new bone formatio...
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220120006035/en/ Karen Witts (Photo: Business Wire) Ipsen (Euronext: IPN; ADR: IPSEY) announced today the nomination of Karen Witts to its Bo...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Genfit (NASDAQ: GNFT ) stock is rocketing higher on Friday after the company signed an exclusive licensing agreement with Ipsen (OTCMKTS: IPSEY ). Source: Shutterstock Let’s dive into that recent ...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...